市場調査レポート
商品コード
1492506
女性不妊症の診断と治療市場:製品、治療、診断、不妊原因、エンドユーザー別-2024-2030年の世界予測Female Infertility Diagnosis & Treatment Market by Product (Accessories, Equipment, Media), Treatment (Assisted Reproductive Technology, Medication, Surgery), Diagnosis, Cause of Infertility, End User - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
女性不妊症の診断と治療市場:製品、治療、診断、不妊原因、エンドユーザー別-2024-2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
|
女性不妊症の診断と治療市場規模は2023年に18億1,000万米ドルと推定され、2024年には19億6,000万米ドルに達し、CAGR 8.11%で2030年には31億4,000万米ドルに達すると予測されています。
女性不妊症の診断と治療は、女性の不妊症に関連する原因と治療に対処するために包括的に構成されています。ホルモン評価や画像検査から、体外受精(IVF)や外科的介入を含む高度生殖補助医療(ART)に至るまで、診断・治療ソリューションが統合されています。初産婦の高年齢化、肥満率の上昇、PCOSを含む関連する健康状態などのライフスタイル要因の変化による女性の不妊率の増加が、女性の不妊診断・治療の必要性を高めています。さらに、不妊問題に対する意識の高まりと、治療を受けることに対する社会的受容の拡大が市場の成長を支えています。しかし、ARTやその他の不妊治療には高額な費用がかかるため、女性不妊診断・治療の導入には限界があります。さらに、女性不妊症の診断と治療におけるAIと機械学習の統合は、診断精度を向上させ、治療結果を予測し、全体的な治療効果を高め、将来の成長をサポートします。
主な市場の統計 | |
---|---|
基準年[2023] | 18億1,000万米ドル |
予測年[2024] | 19億6,000万米ドル |
予測年 [2030] | 31億4,000万米ドル |
CAGR(%) | 8.11% |
地域別インサイト
南北アメリカでは、高い消費者意識、強固なヘルスケアインフラ、有利な政府政策により、不妊治療に対する強いニーズが高まっています。特に米国とカナダは、個別化医療の最前線にあり、関連研究に多額の投資を行っているため、革新的な治療法の選択肢が広がっています。南米の女性不妊症の診断と治療市場は、認知度の向上と医療介入の利用可能性の増加により、顕著な市場開拓が進んでいます。強固なヘルスケアシステムと規制を持つ欧州は、高い患者ケアとデータ安全基準を保証し、不妊治療のための信頼できる環境を育んでいます。中東・アフリカでは、ヘルスケア投資の拡大と不妊治療関連の施設やサービスの充実が市場成長の原動力となっています。アジア太平洋地域は、費用対効果の高い治療と医療水準の向上により、医療ツーリズムの拠点となっています。中国とインドでは、消費者のニーズはコスト、文化的受容性、技術の利用可能性によって左右されます。これらの国々の都市部は、所得水準が高く、認知度が高いため、先進医療を採用する傾向が高いです。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、女性不妊症の診断と治療市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、ビジネス戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、女性不妊症の診断と治療市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、女性不妊症の診断と治療市場における現在の立ち位置を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[195 Pages Report] The Female Infertility Diagnosis & Treatment Market size was estimated at USD 1.81 billion in 2023 and expected to reach USD 1.96 billion in 2024, at a CAGR 8.11% to reach USD 3.14 billion by 2030.
The female infertility diagnosis & treatment are comprehensively structured to address the causes and treatments associated with infertility in women. It integrates diagnostic and therapeutic solutions, from hormonal assessments and imaging tests to advanced assisted reproductive technologies (ART), including in vitro fertilization (IVF) and surgical interventions. Increased infertility rates in females due to changes in lifestyle factors, such as higher age of first-time mothers, rising obesity rates, and associated health conditions, including PCOS, are raising the need for female infertility diagnosis & treatments. Moreover, growing awareness about fertility issues and greater social acceptance for seeking treatment support market growth. However, the high cost of ART and other infertility treatment limits patients to adopt female infertility diagnoses and treatments. Furthermore, the integration of AI and machine learning in female infertility diagnosis & treatment improves diagnostic accuracy and predict treatment outcomes, enhancing overall treatment efficacy and supporting future growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.81 billion |
Estimated Year [2024] | USD 1.96 billion |
Forecast Year [2030] | USD 3.14 billion |
CAGR (%) | 8.11% |
Regional Insights
In the Americas, high consumer awareness, robust healthcare infrastructure, and favorable government policies drive a strong need for infertility treatments. The countries, notably the United States and Canada, are at the forefront of adopting personalized medicine approaches and investing heavily in related research, thus pushing the envelope in innovative treatment options. The South American market for female infertility diagnosis & treatment is undergoing notable development, driven by enhanced awareness and the increasing availability of medical interventions. Europe, with its robust healthcare systems and regulations, ensures high patient care and data safety standards, fostering a reliable environment for infertility treatments. In the Middle East and Africa, growing healthcare investments and enhancing facilities and services related to infertility treatments drive market growth. The Asia Pacific region is a hub for medical tourism due to cost-effective treatments and rising healthcare standards. In China and India, consumer needs are driven by cost, cultural acceptance, and technology availability. Urban areas in these countries show a higher propensity for adopting advanced medical treatments due to higher income levels and better awareness.
Market Insights
The market dynamics represent an ever-changing landscape of the Female Infertility Diagnosis & Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Female Infertility Diagnosis & Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Female Infertility Diagnosis & Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Lupin Introduces New Generic Infertility Treatment in the U.S. Market
Lupin Limited announced the U.S. launch of its Ganirelix Acetate Injection, 250 mcg/0.5 mL, in a Single-Dose Prefilled Syringe, following the United States Food and Drug Administration (FDA) approval. This product is the generic version of Organon USA LLC's Ganirelix Acetate Injection and is designed to prevent premature luteinizing hormone rise in women undergoing controlled ovarian hyperstimulation. [Published On: 2024-02-16]
Arva Health's Innovative At-Home Fertility Test for Indian Women
Arva Health introduced an at-home fertility test developed with leading fertility experts. This test uniquely measures up to 12 hormonal levels pertinent to fertility, allowing women to conveniently assess their reproductive health from home. This is both cost-effective and non-intrusive compared to traditional clinic visits. Arva Health illuminates aspects of the biological clock and potential reproductive issues and equips women with the knowledge to manage their fertility journey proactively at their convenience and discretion. [Published On: 2023-12-13]
Trajan Scientific and German Startup Fertilly Introduce Microsampling-based Fertility Test Kits in Europe
Trajan Scientific and Medical partnered with Fertility to launch Europe's first-at-home fertility test kits. These kits incorporate advanced dried blood microsampling technology. Fertilly's move, supported by Trajan Scientific's innovative technologies, represents a crucial step towards democratizing fertility assessments and enabling more informed decisions regarding family planning. [Published On: 2023-08-15]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Female Infertility Diagnosis & Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Female Infertility Diagnosis & Treatment Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Cook Group Incorporated, CooperSurgical Inc., Ferring B.V., FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation, Genea Pty Limited, GlaxoSmithKline PLC, Halotech DNA S.L., Intas Pharmaceuticals Ltd., Lupin Limited, Merck & Co., Inc., Novartis AG, Sanofi SA, SCSA Diagnostics, Inc., Theramex by Kanga Health Ltd, and Vitrolife Sweden AB.
Market Segmentation & Coverage